




Supplemental Data: Related to “Synthesis of DPP and FP Substrate Analogue Inhibitors” Spectroscopic and Spectrometric Characterization of Compounds




¹H NMR spectrum of 7 in d₆-DMSO.




³¹P NMR spectrum of 7 in d₆-DMSO.




¹³C NMR of 7 in d₆-DMSO.




¹H NMR of 8, diastereomer 1 (D1) in CDCl₃.




^{31}P NMR of **8**, diastereomer 1 (D1) in CDCl_3 .




^{13}C NMR of **8**, diastereomer 1 (D1) in CDCl_3 .




¹H NMR of **8** (~1:1 mixture of diastereomers 1 and 2) in CDCl₃.




³¹P NMR of **8** (~1:1 mixture of diastereomers 1 and 2) in CDCl₃.




¹H NMR of **9**, diastereomer 1 (D1) in CDCl₃.




³¹P NMR of **9**, diastereomer 1 (D1) in CDCl₃.




¹³C NMR of 9, diastereomer 1 (D1) in CDCl₃.




¹H NMR of 9, diastereomer 2 (D2) enriched ~5:1 in CDCl₃.




³¹P NMR of **9**, diastereomer 2 (D2) enriched ~5:1 in CDCl₃.




¹³C NMR of **9**, diastereomer 2 (D2) enriched ~5:1 in CDCl₃.




¹H NMR of **10**, diastereomer 1 (D1) in d₆-DMSO.




³¹P NMR of **10**, diastereomer 1 (D1) in d₆-DMSO.




¹³C NMR of **10**, diastereomer 1 (D1) in d₆-DMSO.




¹H NMR of **10**, diastereomer 2 (D2) enriched ~3:1 in d₆-DMSO.




³¹P NMR of **10**, diastereomer 2 (D2) enriched ~3:1 in d₆-DMSO.




¹³C NMR of **10**, diastereomer 2 (D2) enriched ~3:1 in d₆-DMSO.




¹H NMR of **4**, diastereomer 1 (D1) in d₆-DMSO.




³¹P NMR of **4**, diastereomer 1 (D1) in d₆-DMSO.




¹³C NMR of 4, diastereomer 1 (D1) in d₆-DMSO.




¹H NMR of 4, diastereomer 2 (D2) in d₆-DMSO.




³¹P NMR of **4**, diastereomer 2 (D2) in d₆-DMSO.




¹³C NMR of **4**, diastereomer 2 (D2) in d₆-DMSO. Unaccounted for ¹³C-signals were acquired with a DEPT-135 experiment (see Figure S34).




¹³C DEPT-135 of 4, diastereomer 2 (D2) in d₆-DMSO.




UPLC-HRMS analysis of **4**. (Left) UPLC trace of **4**, diastereomers 1 and 2 (D1 and D2). (Right) Mass spectra of **4**, diastereomers 1 and 2 (D1 and D2).




¹H NMR of **5**, diastereomer 1 (D1) in d₆-DMSO.




³¹P NMR of **5**, diastereomer 1 (D1) in d₆-DMSO.




¹H NMR of 5, diastereomer 2 (D2) in d₆-DMSO.




³¹P NMR of 5, diastereomer 2 (D2) in d₆-DMSO.





UPLC-HRMS analysis of **5**. (Left) UPLC trace of **5**, diastereomers 1 and 2 (D1 and D2). (Right) Mass spectra of **5**, diastereomers 1 and 2 (D1 and D2).



^{31}P NMR of **12** as a ~1:1 diastereomeric mixture. Characterization by ^1H and ^{19}F NMR was impeded by dramatic line broadening likely due to multiple charge-states and slow ion-pair exchange.



UPLC-HRMS analysis of **12** (~1:1 diastereomeric mixture). (Left, Bottom) UPLC trace of **12**. (Left, Top) Extracted ion chromatogram (EIC) of **12**, $m/z = 424.107 \pm 0.05$, indicating that the free fluorophosphonate elutes at different retention times, likely due to differences between diastereomers and different protonation-states. (Right) Mass spectrum of **12**.






Figure 38. ^{31}P NMR of racemic **13** in d_6 -DMSO.




Figure 39. ^{13}C NMR of racemic **13** in d_6 -DMSO.